Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Non-Hodgkin Lymphoma Therapeutics Market

Non-Hodgkin Lymphoma Therapeutics Market Trends

Report ID: GMI9696
Published Date: May 2024
Report Format: PDF

Download Free Sample

Non-Hodgkin Lymphoma Therapeutics Market Trends

The expanded funding and intensified R&D activities facilitated the advancement of innovative therapies, spanning targeted treatments, immunotherapies, and chemotherapy protocols, thereby driving market growth.

For instance, the Leukemia & Lymphoma Society (LLS) has awarded a USD 5 million grant to researchers at Washington University School of Medicine in St. Louis to advance research in creating novel immunotherapies for various blood-based cancers. This funding supports 2-3 projects, including research on T-cell Non-Hodgkin lymphoma treatment, aiming to broaden research efforts for potential blood cancer therapeutics, including lymphoma.

Thus, ongoing research for the development of combined therapies and innovative approaches to enhance treatment effectiveness coupled with growing partnerships among pharmaceutical, academic, and research institutions are few factors fostering the expansion of market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Non-Hodgkin lymphoma therapeutics industry size was worth USD 9.5 billion in 2023 and is projected to expand at 7.4% CAGR from 2024 to 2032, due to the increasing prevalence of non-Hodgkin lymphoma worldwide.

The B-cell lymphomas type segment in the non-Hodgkin lymphoma therapeutics industry is estimated to record USD 9.6 billion by 2032, as these treatments enhance response rates and improve patient outcomes.

The radiation therapy segment in the non-Hodgkin lymphoma therapeutics industry accounted for 45.4% market share in 2023, due to the rising initiatives from key market players, including product launches and partnerships.

U.S. non-Hodgkin lymphoma therapeutics market recorded USD 3.9 billion in 2023 and is anticipated to grow at significant rate between 2024 and 2032, owing to the presence of advanced healthcare infrastructure, robust research and development environment, and substantial investments in cancer therapies.